Biotechnology major Biocon on Tuesday said it aims to achieve revenues of $1 billion in the next three years.
"Our target is to do it in the next three fiscals," Biocon Chairman and Manging Director Kiran Mazumdar Shaw told
PTI on the sidelines of an event here to announce the dates and details of India Bio 2012.
Speaking about the future plans, Shaw said, "We see ourselves among the top 10 global biotechnological companies in the world."
On the main drivers of future growth, she said, "Our main emphasis is on the chronic diseases.
The main emphasis is on diabetes, cancer and auto
immune diseases." The company also has plans to list its contract research and manufacturing services arm Syngene.